Sébastien M.
- Country
- France
- Department
- Hematology
Research Overview
- Evaluation of Blinatumomab, Isatuximab, and Ponatinib in Frontline Therapy for Adults with Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma
- Blinatumomab and Combination Therapy Versus Standard of Care in Older Adults With Newly Diagnosed Philadelphia-Negative B-Cell Precursor Acute Lymphoblastic Leukemia
- Randomized Precision Medicine Trial of Venetoclax Combination Therapy in Relapsed/Refractory T‑Cell Acute Lymphoblastic Leukemia
Data & Insights
Has run more than one trial at 68 of 154 partner sites.
Specializations
Myelodysplastic Syndromes
The investigator specializes in treating myelodysplastic syndrome (MDS), with particular focus on cases involving specific genetic mutations such as IDH1 and IDH2. Their research encompasses novel therapeutic approaches for MDS patients, including targeted treatments and stem cell transplantation strategies.
- Mutation-specific therapies
- Allogeneic transplantation
- Graft versus host disease prevention
Acute Leukemias
The investigator has extensive experience in treating various forms of acute leukemia, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Their work focuses on developing innovative treatment protocols for different age groups and genetic subtypes.
- Philadelphia-positive B-ALL
- T-cell ALL
- Immunotherapy applications
Myeloproliferative Disorders
The investigator conducts research in the treatment of myelofibrosis, exploring advanced therapeutic options including haploidentical transplantation approaches. Their work encompasses both primary and secondary forms of the disease.
- Haploidentical transplantation
- Disease-free survival strategies
- Novel conditioning regimens
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.